BeyondSpring Inc

Follow
Verify
From Verify.Wiki
Jump to: navigation, search
Beyond.png
www.beyondspringpharma.com/
BeyondSpring Inc
Type Public
Industry Pharmaceuticals
Founded 2013
Headquarters New York, NY, United States
Key people Lan Huang (Co-Founder, CEO), Richard A. Brand (CFO), Ramon W. Mohanlal (Chief Medical Officer), Gordon L. Schooley (Chief Regulatory Officer) [1]
Number of employees 20 [2]

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. It focuses on the development of innovative immuno-oncology cancer therapies. Its products in pipeline includes Plinabulin, an immuno-oncology agent in Phase 3 clinical trial for the reduction of Docetaxel-induced Neutropenia and another Phase 3 clinical trial as an anticancer agent in combination with Docetaxel in advanced non-small cell lung cancer. [3]


Products

Plinabulin is an anti-cancer agent with a unique mechanism of action. It is a multi-target agent that has been shown to exhibit anti-tumor activity through anti-angiogenesis, obliteration of existing tumor vasculature and induction of tumor cell apoptosis via the JNK pathway. [4]
Plinabulin has the potential to fill an unmet medical need by improving outcomes as a second line and third line treatment for patients with advanced non-small cell lung cancer (NSCLC) and preventing neutropenia induced by docetaxel. [5]
As a tubulin depolymerizing agent, Plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment:

  1. Immune enhancing effects via dendritic cell maturation
  2. Tumor cell apoptosis via activation of RAS-JNK pathway
  3. Vascular disruptive effects

Given Plinabulin’s potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications:

  • Immuno-oncology, with immune checkpoint inhibitors in NSCLC
  • CNS malignancies including glioblastoma (GBM)
  • KRAS positive mutant cancers

[6]

Controversies

Top 5 Recent Tweets

DateAuthorComment
June 20, 2018goldmanblogTOday’s Movers: Beyondspring Inc $//goldmanblog.com/2018/06/20/todays-movers-beyondspring-inc-bysi-stock-rating-rei… https://t.co/jU7BpYEspX
June 20, 2018reurope_stockBreaking: Beyondspring Inc $BYSI Buy Rating Reiterated at H.C. Wainwright Today; The Price Objective is Set to $60.0000 ...
June 20, 2018weeklyhubKey Research Analysts at H.C. Wainwright Reiterated their ‘Buy’ rating for Beyondspring Inc $BYSI Shares Today. The… https://t.co/uThAmKYXfb
June 20, 2018bzweeklyReaffirmed: Beyondspring Inc $//bzweekly.com/2018/06/20/reaffirmed-beyondspring-inc-bysi-buy-rating-maintained-at-h… https://t.co/4KWJh0bnUz


Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines

  1. http://www.beyondspringpharma.com/en/about/management/
  2. http://www.nasdaq.com/markets/ipos/company/beyondspring-inc-1008377-82102
  3. http://www.bloomberg.com/Research/stocks/private/snapshot.asp?privcapid=318874853
  4. http://www.fiercebiotech.com/biotech/beyondspring-pharmaceuticals-names-dr-yan-sun-as-principal-investigator-for-global-phase-3
  5. http://www.beyondspringpharma.com/en/plinabulin/
  6. https://www.linkedin.com/company/beyondspring-pharmaceuticals

Verification history